Development and application of SA-Biotin bridge-based cell marking improved electrofusion method
The SA-Biotin bridge system labels heterologous cells and optimizes the electrofusion program, which solves the problems of low fusion rate and positive rate caused by different sizes of heterologous cells, significantly improves the formation and screening efficiency of hybridoma cells, and provides a high efficiency Improved electrofusion method for cell labeling.
Patent Information
- Application Number
- CN202411451674.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-17
- Publication Date
- 2024-11-22
AI Technical Summary
The existing electrofusion technology in hybridoma cell production has low fusion rate and positive rate due to different heterologous cells, and there is a situation where homologous cells are fused together, which affects the screening efficiency.
The SA-Biotin bridge system was used to label heterologous cells, and the specific binding of biotin and streptavidin increased cell contact rate and fusion efficiency were optimized to improve the formation rate and positive screening rate of hybridoma cells.
It significantly improves the fusion rate of heterologous cells and the positive cloning formation rate, reduces homologous cell fusion, enhances the contact area of heterologous cells, and improves the screening efficiency of hybridoma cells.
Smart Images

Figure CN118995693A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of hybridoma cell preparation, and specifically relates to the development and application of a cell labeling improved electrofusion method based on SA-Biotin bridge. Background Art
[0002] Cell fusion is a key step in the preparation of monoclonal antibodies. The quality of fusion determines the ratio of positive clones screened, so the cell fusion process needs to be controlled. At present, electrofusion technology has been widely used in the production of hybridoma cells. Electrofusion uses a short and strong pulsed electric field to increase the permeability of the cell membrane. The pulsed electric field produces local perforations on the cell membrane, thereby inducing cell fusion. The efficiency of electrofusion is much higher than that of the conventional polyethylene glycol method, and more fused cells can be produced. However, due to the size difference between the two heterologous cells, it is impossible to ensure that the two heterologous cells contact each other in the fusion pool to form hybridoma cells. There is a situation where homologous cells fuse with each other, resulting in problems such as low hybridoma fusion rate and low positive rate.
[0003] Streptavidin (SA) is a protein of about 55 kDa secreted by Streptomyces. It has a very unique affinity with biotin and is one of the strongest non-covalent bonds in nature. A SA protein can bind four biotin molecules with high affinity and selectivity. The complex they form is very stable and can be connected to molecules, labels or supports that need to be coupled and fixed, and is not easy to dissociate. The SA-Biotin system has the characteristics of high affinity, strong specificity, and good stability, and is therefore widely used in biological research. Therefore, using the SA-Biotin system to label two heterologous cells can greatly increase the contact rate of the two heterologous cells and improve the cell fusion rate and positive rate. Summary of the invention
[0004] The purpose of the present invention is to overcome the technical shortcomings of the existing traditional cell fusion and provide a cell-marking improved electrofusion method for preparing hybridoma cells based on the SA-Biotin bridge. The present invention aims to reduce the probability of fusion of the same cells by marking the cells to be fused with SA and Biotin, increase the contact opportunities of heterologous cells during the electrofusion arrangement process, further improve the fusion efficiency of hybridoma cells prepared by the electrofusion method, and maximize the positive rate of the screening project.
[0005] The present invention is specifically achieved through the following technical solutions: The present invention provides a cell labeling improved electrofusion method based on SA-Biotin bridge, comprising the following steps: 1) Mouse spleen cells and SP2 / 0 myeloma cells were respectively prepared into cell suspensions, biotin was added for labeling reaction, and Biotin-labeled spleen cells and Biotin-labeled SP2 / 0 myeloma cells were obtained, which were resuspended for later use; 2) adding streptavidin to the suspension of Biotin-labeled spleen cells obtained in step 1) to perform SA labeling reaction to obtain SA-labeled spleen cells, and resuspending the cells for later use; 3) The obtained Biotin-labeled SP2 / 0 myeloma cells and SA-labeled spleen cells were mixed evenly, washed with electrofusion buffer, and then added to the fusion chamber of the electrofusion instrument that had been rinsed with electrofusion buffer in advance for cell fusion to form fusion products containing hybridoma cells, and finally positive screening was performed.
[0006] Furthermore, the cell suspension in step 1) is prepared using DPBS, and the cell density in the suspension is 1.0×10 7 ~2.5×10 7 / mL; preferably 2.5×10 7 Pieces / mL.
[0007] Furthermore, in step 1), the biotin labeling reaction uses Sulfo-NHS-LC-Biotin, and the amount of Sulfo-NHS-LC-Biotin labeling is 35-70 μg / mL; preferably 50 μg / mL. Biotin uses Sulfo-NHS-LC-Biotin for labeling reaction, which has the advantages of good water solubility, and the long-chain LC fragment can reduce the steric hindrance with SA, which is conducive to the rapid cross-linking reaction between the two. At the same time, it has NHS active esters that can be cross-linked in one step, and the labeling efficiency is high.
[0008] Furthermore, in step 2), the amount of streptavidin in the suspension of biotin-labeled spleen cells is 35-70 μg / mL; the mass ratio of streptavidin to biotin is 1:1.
[0009] Furthermore, in step 3), the ratio of the number of Biotin-labeled SP2 / 0 myeloma cells to the number of SA-labeled spleen cells mixed is 1:(2-5); preferably 1:2.
[0010] Furthermore, in step 3), the parameters of the electrofusion instrument include three AC electric fields and one DC pulse voltage: the first AC electric field parameters are VO: 30 V, VF: 50 V, AC electric field frequency is 2 MHz, and the duration is 20 s; the second AC electric field parameters are VO: 60 V, VF: 60 V, AC electric field frequency is 2 MHz, and the duration is 20 s; the third DC pulse parameters are DC pulse voltage 600 V, action time 50 μs, and pulse number 1; the last AC electric field parameters are VO: 50V, VF: 5 V, AC electric field frequency 0.8 MHz, and duration is 7 s. The electrofusion uses the BTX ECM2001+ fusion instrument.
[0011] The present invention also provides the application of the cell labeling improved electrofusion method based on the SA-Biotin bridge in the field of preparing hybridoma cells and developing monoclonal antibodies.
[0012] The beneficial effects of the present invention are: 1. The present invention proposes a SA-Biotin bridge system to enable spleen cells and SP2 / 0 to indirectly combine before fusion, thereby optimizing the fusion strategy and obtaining the target fusogen to the maximum extent.
[0013] 2. The present invention greatly reduces the fusion probability of SP2 / 0-SP2 / 0 and spleen cell-splenocyte, and improves the hybridoma clone formation rate of SP2 / 0-splenocyte and the positive rate of subsequent screening.
[0014] 3. The electric fusion procedure of the present invention is used to improve the labeled cells, so that they can form a pearl chain of fully arranged SP2 / 0-splenocytes under the action of the electric field, thereby increasing the contact area between heterologous cells and improving the fusion rate of heterologous cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is a schematic diagram of the specific binding between spleen cells and SP2 / 0 under the SA-Biotin system.
[0016] Figure 2 This is a diagram of the cell arrangement state during the fusion process in Example 5 of the present invention.
[0017] Figure 3 It is a bar graph comparing the cell fusion efficiency in Example 5 of the present invention.
[0018] Figure 4 It is a line-bar graph comparing cell survival rate and cell number in Example 5 of the present invention.
[0019] Figure 5 It is a bar graph comparing the number of positive wells in Example 5 of the present invention. DETAILED DESCRIPTION
[0020] In order to make the purpose, technical scheme and advantages of the present invention clearer, the technical scheme of the present invention will be clearly and completely described below in conjunction with the embodiments. If the specific conditions are not specified in the embodiments, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be purchased commercially.
[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0022] Example 1 A method for labeling SP2 / 0 and spleen cells with Biotin, comprising the following steps: Biotin uses Sulfo-NHS-LC-Biotin for labeling reaction, which has the advantage of good water solubility. The long-chain LC fragment can reduce the steric hindrance with SA, which is conducive to the rapid cross-linking reaction between the two. At the same time, it has NHS active esters that can be cross-linked in one step, and the labeling efficiency is high. Use sterile water to prepare a 20 mM mother solution, filter it through a 0.22 μm filter membrane for sterilization, and then label the cells. Note that it should be prepared and used immediately.
[0023] Mouse spleen cells and SP2 / 0 were washed and counted, and then resuspended in DPBS at 4×10 7 splenocytes and 6×10 6 SP2 / 0 cells to a cell density of 2.5 × 10 7 / mL, add 50 μg of Sulfo-NHS-LC-Biotin according to the reaction volume of 1 mL for labeling reaction, incubate at room temperature for 30 min (protect from light, and gently shake occasionally to mix the reaction), centrifuge at 1000 rpm for 3 min after the reaction, wash twice with 3 mL DPBS, and resuspend the labeled cells in 0.5 mL DPBS for use.
[0024] Example 2 A method for labeling splenocytes with SA, comprising the following steps: A certain amount of SA (Biotin: SA = 1:1) was added to the suspension of Biotin-labeled spleen cells obtained in Example 1 for SA labeling reaction, and the mixture was incubated at room temperature for 15 min (protected from light and gently shaken occasionally to mix the reaction). After the reaction, the mixture was centrifuged at 1000 rpm for 3 min, washed once with 3 mL of DPBS, and then the labeled cells were resuspended in 1 mL of DPBS for later use.
[0025] SA was prepared into a 1 mg / mL stock solution using DPBS, and then sterilized by filtration through a 0.22 μm filter membrane before cell SA labeling.
[0026] SA labeling of spleen cells further reduced the size difference between spleen cells and SP2 / 0, which was conducive to the two cells moving closer together under electric field stimulation and increased the probability of contact arrangement.
[0027] Example 3 A method for forming a composite cell of splenocyte-SA-Biotin-SP2 / 0 specific bridge with Biotin-SP2 / 0 and SA-splenocytes, the principle of which is as follows Figure 1 As shown, the preparation steps are as follows: The Biotin-labeled SP2 / 0 cells obtained in Example 1 and the SA-labeled spleen cells obtained in Example 2 were gently mixed at a ratio of 1:2, and placed at room temperature for 15 min (protected from light, and occasionally gently shaken to mix the reaction) for affinity binding, centrifuged at 1000 rpm for 3 min, and the supernatant was discarded for electrofusion.
[0028] Biotin-labeled SP2 / 0 cells and SA-labeled spleen cells are tightly bound together through the specific affinity of SA-Biotin. Usually, one SA molecule can bind to four Biotin molecules. In order to prevent one SP2 / 0 from binding to multiple spleen cells, the amount of SA input is reduced, and the binding ratio of SP2 / 0 to spleen cells is reduced at the same time.
[0029] Example 4 The cell labeling improved electrofusion method based on SA-Biotin bridge has the following steps: 1. Under sterile conditions, prepare a mouse spleen cell suspension and count the cells. The mouse spleen cells and the SP2 / 0 myeloma cells collected and counted in advance are labeled with Biotin according to Example 1.
[0030] 2. The Biotin-labeled spleen cells in step 1 are further labeled with SA according to Example 2.
[0031] 3. The Biotin-labeled SP2 / 0 cells and SA-labeled spleen cells obtained in steps 1 and 2 were specifically combined according to the method steps of Example 3; 5 mL of electrofusion buffer (Beijing Beihui Technology) was added for washing, centrifuged at 1000 rpm for 3 min, and the operation was repeated twice.
[0032] 4. Prepare the fusion chamber of the electrofusion instrument (BTX ECM2001+) by rinsing it with electrofusion buffer in advance, and set the fusion parameters in advance, including three AC electric fields and one DC pulse voltage: The first AC electric field allowed the cells to begin pre-arrangement, with the following parameters: VO: 30 V, VF: 50 V, AC electric field frequency 2 MHz, and duration of action 20 s; The second AC electric field allowed the cells to align evenly, with the following parameters: VO: 60 V, VF: 60 V, AC electric field frequency 2 MHz, and duration of action 20 s. The third direct current pulse is the key to cell fusion, and the specific parameters are: direct current pulse voltage 600 V, action time 50 μs, pulse number 1; The last AC electric field restored the cell state. The specific parameters were: VO: 50 V, VF: 5 V, AC electric field frequency 0.8 MHz, and duration of action 7 s.
[0033] 5. Add the cell suspension from step 3 to the fusion chamber of the electrofusion instrument that has been pre-rinsed with buffer. Be careful not to generate bubbles when adding. Fusion should be performed within 30 s after addition. The cell fusion density should be controlled at 0.5-1×10 7 Pieces / mL.
[0034] 6. Perform cell fusion according to the electrofusion procedure in step 4 to form fusion products containing hybridoma cells.
[0035] 7. After the fusion is completed, let the cells stand in the fusion pool for 2 minutes, then transfer them to the HAT complete culture medium prepared in advance, and incubate them in a 37°C incubator for 60 minutes to allow the cells to adapt and recover.
[0036] 8. Add the fused cell suspension to a 96-well plate with feeder cells and culture for 7 days, followed by screening of positive wells.
[0037] Comparative Example 1 A method for preparing hybridoma cells by conventional electrofusion, wherein the preparation method is the same as steps 4-8 of Example 4, except that the splenocytes and SP2 / 0 are not labeled.
[0038] Comparative Example 2 A method for preparing hybridoma cells by PEG chemical fusion method, the steps of which are as follows: 1. Under sterile conditions, prepare mouse spleen cell suspension and perform cell count.
[0039] 2. Mix mouse spleen cells and pre-collected SP2 / 0 myeloma cells in a ratio of 5:1, discard the supernatant after centrifugation, and tap the cells to make them evenly distributed.
[0040] 3. Slowly add 1 mL of 50% PEG solution within 1 min and let stand for 1 min to allow the spleen cells and SP2 / 0 to fully react and fuse.
[0041] 4. Then, add 15 mL of Free DMEM culture medium from slow to fast over 5 minutes to terminate the effect of PEG.
[0042] 5. After centrifugation, resuspend the fused cells in HAT selective medium, add the fused cell suspension to a 96-well plate with feeder cells and culture for 7 days, followed by positive well screening.
[0043] Example 5 Example 4 and Comparative Examples 1-2 were used to prepare hybridoma cells of Project A and Project B with different targets, respectively, and the effects of improved electrofusion, traditional electrofusion and PEG chemical fusion in preparing hybridoma cells were evaluated. The cells of the three fusion methods were arranged as follows Figure 2 As shown in the figure (A is PEG fusion, B is traditional electrofusion, and C is improved electrofusion), the fusion efficiency comparison is Figure 3 The comparison of cell survival rate and cell number is shown in Figure 4 As shown, the number of screening positive wells is compared with Figure 5 As shown in the figure, fusion efficiency‰=total number of hybridoma colonies in each well / number of spleen cells×1000.
[0044] Results analysis: According to the comparison of the cell fusion rate, number of positive holes, number of cells and viability of the three fusion methods of the improved electrofusion method, traditional electrofusion method and PEG chemical method of the SA-Biotin bridge of Project A and Project B, it was found that the cell fusion rate of the electrofusion method was significantly higher than that of the PEG chemical method, about 20 times, and the number of strong positive holes was better than that of the PEG fusion method, mainly because the electrofusion method was mild, the stimulation was short, and the cells could recover quickly, while the PEG method had a large and irreversible toxic effect on cells, affecting the survival of cells and resulting in lower fusion efficiency. Further analysis of the fusion effect of the improved electrofusion and traditional electrofusion projects showed that the improved electrofusion efficiency of the present invention was higher than that of the traditional electrofusion efficiency, about 1.3 times, but the number of cells and viability were slightly lower than those of the traditional electrofusion, mainly because the labeling of biotin streptavidin affected the state and viability of the cells to a certain extent, causing certain damage to the cells. The number of positive holes based on the SA-Biotin improved electrofusion was higher than that of the traditional electrofusion, mainly because the improved electrofusion increased the fusion efficiency of heterologous cells and formed more hybrids, thereby increasing the positive rate. Therefore, the improved electrofusion can be used in subsequent electrofusion projects for hybridoma cell preparation to improve the fusion quality.
[0045] In summary, the cell-labeled improved electrofusion method based on SA-Biotin bridge of the present invention provides a new idea for preparing monoclonal antibodies using hybridoma technology. This method is simple to operate and has obvious effects. It enhances the contact probability of heterologous cells through specific affinity, thereby obtaining more target hybridoma fusions. Compared with other fusion methods, it has a higher fusion rate, is conducive to screening more target positive clones, and has broad application prospects in hybridoma cell preparation.
[0046] The embodiments described above only express several preferred embodiments of the present invention, and the descriptions thereof are relatively specific and detailed, but are not intended to limit the present invention. It should be noted that for those skilled in the art, the present invention may also have various changes and modifications, and any modifications, equivalent substitutions, improvements, etc. made within the concept and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A cell labeling and improved electrofusion method based on SA-Biotin bridge, characterized in that: The steps include: 1) Mouse spleen cells and SP2 / 0 myeloma cells were respectively prepared into cell suspensions, biotin was added for labeling reaction, and Biotin-labeled spleen cells and Biotin-labeled SP2 / 0 myeloma cells were obtained, which were resuspended for later use; 2) adding streptavidin to the suspension of Biotin-labeled spleen cells obtained in step 1) to perform SA labeling reaction to obtain SA-labeled spleen cells, and resuspending the cells for later use; 3) The obtained Biotin-labeled SP2 / 0 myeloma cells and SA-labeled spleen cells were mixed evenly, washed with electrofusion buffer, and then added to the fusion chamber of the electrofusion instrument that had been rinsed with electrofusion buffer in advance for cell fusion to form fusion products containing hybridoma cells, and finally positive screening was performed.
2. The cell labeling improved electrofusion method based on SA-Biotin bridge according to claim 1, characterized in that: Step 1) The cell suspension was prepared using DPBS, and the cell density in the suspension was 1.0×10 7 ~2.5×10 7 Pieces / mL.
3. The cell labeling improved electrofusion method based on SA-Biotin bridge according to claim 1, characterized in that: In step 1), the biotin labeling reaction uses Sulfo-NHS-LC-Biotin, and the amount of Sulfo-NHS-LC-Biotin labeling is 35-70 μg / mL.
4. The cell labeling improved electrofusion method based on SA-Biotin bridge according to claim 1, characterized in that: In step 2), the amount of streptavidin used in the suspension of biotin-labeled spleen cells is 35-70 μg / mL; the mass ratio of streptavidin to biotin is 1:
1.
5. The cell labeling improved electrofusion method based on SA-Biotin bridge according to claim 1, characterized in that: In step 3), the ratio of the number of Biotin-labeled SP2 / 0 myeloma cells and SA-labeled spleen cells mixed is 1:(2-5).
6. The cell labeling improved electrofusion method based on SA-Biotin bridge according to claim 1, characterized in that: Step 3) The parameters of the electrofusion instrument include three AC electric fields and one DC pulse voltage: the first AC electric field parameters are VO: 30 V, VF: 50 V, the AC electric field frequency is 2 MHz, and the duration of action is 20 s; the second AC electric field parameters are VO: 60 V, VF: 60 V, the AC electric field frequency is 2 MHz, and the duration of action is 20 s; the third DC pulse parameters are DC pulse voltage of 600 V, action time of 50 μs, and the number of pulses is 1; the last AC electric field parameters are VO: 50 V, VF: 5 V, the AC electric field frequency is 0.8 MHz, and the duration of action is 7 s.
7. Application of the cell labeling improved electrofusion method based on SA-Biotin bridge as claimed in any one of claims 1 to 6 in the field of preparing hybridoma cells and developing monoclonal antibodies.
